Vis enkel innførsel

dc.contributor.authorYoon, Minjae
dc.contributor.authorLee, Ji Hyun
dc.contributor.authorKim, In-Cheol
dc.contributor.authorLee, Ju-Hee
dc.contributor.authorKim, Mi-Na
dc.contributor.authorKim, Hack-Lyoung
dc.contributor.authorLee, Sunki
dc.contributor.authorKim, In Jai
dc.contributor.authorChoi, Seonghoon
dc.contributor.authorPark, Sung-Ji
dc.contributor.authorHur, Taeho
dc.contributor.authorHussain, Musarrat
dc.contributor.authorLee, Sungyoung
dc.contributor.authorChoi, Dong-Ju
dc.date.accessioned2024-12-17T15:05:53Z
dc.date.available2024-12-17T15:05:53Z
dc.date.issued2024-11-21
dc.description.abstractBackground: Adherence to oral anticoagulant therapy is essential to prevent ischemic stroke in patients with atrial fibrillation (AF).<p> <p>Objective: This study aimed to evaluate whether smartphone app–based interventions improve medication adherence in patients with AF.<p> <p>Methods: This open-label, multicenter randomized controlled trial (ADHERE-App [Self-Awareness of Drug Adherence to Edoxaban Using an Automatic App Feedback System] study) enrolled patients with AF treated with edoxaban for stroke prevention. They were randomly assigned to app-conditioned feedback (intervention; n=248) and conventional treatment (control; n=250) groups. The intervention group received daily alerts via a smartphone app to take edoxaban and measure blood pressure and heart rate at specific times. The control group received only standard, guideline-recommended care. The primary end point was edoxaban adherence, measured by pill count at 3 or 6 months. Medication adherence and the proportion of adequate medication adherence, which was defined as ≥95% of continuous medication adherence, were evaluated.<p> <p>Results: Medication adherence at 3 or 6 months was not significantly different between the intervention and control groups (median 98%, IQR 95%-100% vs median 98%, IQR 91%-100% at 3 months, P=.06; median 98%, IQR 94.5%-100% vs median 97.5%, IQR 92.8%-100% at 6 months, P=.15). However, the proportion of adequate medication adherence (≥95%) was significantly higher in the intervention group at both time points (76.8% vs 64.7% at 3 months, P=.01; 73.9% vs 61% at 6 months, P=.007). Among patients aged >65 years, the intervention group showed a higher medication adherence value and a higher proportion of adequate medication adherence (≥95%) at 6 months.<p> <p>Conclusions: There was no difference in edoxaban adherence between the groups. However, the proportion of adequate medication adherence was higher in the intervention group, and the benefit of the smartphone app–based intervention on medication adherence was more pronounced among older patients than among younger patients. Given the low adherence to oral anticoagulants, especially among older adults, using a smartphone app may potentially improve medication adherence.en_US
dc.identifier.citationYoon, Lee, Kim, Lee, Kim, Kim, Lee, Kim, Choi, Park, Hur, Hussain, Lee, Choi. Smartphone App for Improving Self-Awareness of Adherence to Edoxaban Treatment in Patients With Atrial Fibrillation (ADHERE-App Trial): Randomized Controlled Trial. Journal of Medical Internet Research (JMIR). 2024;26en_US
dc.identifier.cristinIDFRIDAID 2329570
dc.identifier.doi10.2196/65010
dc.identifier.issn1439-4456
dc.identifier.issn1438-8871
dc.identifier.urihttps://hdl.handle.net/10037/36036
dc.language.isoengen_US
dc.publisherJMIR Publicationsen_US
dc.relation.journalJournal of Medical Internet Research (JMIR)
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleSmartphone App for Improving Self-Awareness of Adherence to Edoxaban Treatment in Patients With Atrial Fibrillation (ADHERE-App Trial): Randomized Controlled Trialen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution 4.0 International (CC BY 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution 4.0 International (CC BY 4.0)